产品描述信息
NR-2634?? Genomic DNA from Vaccinia Virus, Modified Vaccinia Ankara (MVA) (Nucleic Acids)|Vaccinia virus|Genomic DNA from Vaccinia Virus, Modified Vaccinia Ankara (MVA) |-20°C or colder|LS Wyatt, B MossAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Genomic DNA from Vaccinia Virus, Modified Vaccinia Ankara (MVA), NR-2634."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
This item is currently in our production queue. Please allow ample time for distribution lots to be made available.
NR-2634, lot 62153956, genomic DNA was isolated from a preparation of cell lysate and supernatant from chicken embryo fibroblast cells (ATCC ? CRL-1590?) infected with vaccinia virus, MVA (BEI Resources NR-1).
NR-2634, lot 5075330, genomic DNA was isolated from a preparation of cell lysate and supernatant from hamster kidney cells (BHK-21; ATCC ? CCL-10?) infected with vaccinia virus, MVA (BEI Resources NR-1).
MVA is a highly attenuated strain of vaccinia virus and does not appear to replicate in most mammalian cells. The complete genomic sequence of MVA has been determined (GenBank: U94848).
NR-2634 has been qualified for PCR applications by amplification of a > 1,000 bp sequence.
Each vial of NR-2634, lot 62153956 contains 100 ?L of viral genomic DNA in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.0). The viral genomic DNA is in a background of cellular nucleic acid. The vial should be centrifuged prior to opening.
Each vial of NR-2634, lot 5075330, which is no longer available, contained a target amount of 1 × 108 copies of viral genomic DNA in TE buffer (pH 7.5) containing sodium azide.